SRY-box transcription factor 7 functions as a tumor suppressor regulating Wnt signaling and cancer stemness with its promoter methylation as a potential biomarker.
[BACKGROUND] Wnt signaling, critical for development, is often dysregulated in cancer via genetic or/and epigenetic changes.
APA
Xie L, Zhou J, et al. (2026). SRY-box transcription factor 7 functions as a tumor suppressor regulating Wnt signaling and cancer stemness with its promoter methylation as a potential biomarker.. Cellular signalling, 112556. https://doi.org/10.1016/j.cellsig.2026.112556
MLA
Xie L, et al.. "SRY-box transcription factor 7 functions as a tumor suppressor regulating Wnt signaling and cancer stemness with its promoter methylation as a potential biomarker.." Cellular signalling, 2026, pp. 112556.
PMID
42025888
Abstract
[BACKGROUND] Wnt signaling, critical for development, is often dysregulated in cancer via genetic or/and epigenetic changes. SOX7, a high mobility group protein, is downregulated in cancers, but its alterations and underlying mechanism in gastric cancer (GsCa) pathogenesis remain to be clearly defined.
[METHODS] SOX7 mRNA expression and promoter methylation were analyzed in GsCa. Functional impacts were assessed through assays for colony formation, proliferation (CCK-8), cell cycle/apoptosis (flow cytometry), migration/invasion (wound healing, Transwell), and ferroptosis. Mechanistic studies involving Western blot, immunofluorescence, dual-luciferase reporter assays, chromatin immunoprecipitation (ChIP)-qPCR, and bidirectional rescue experiments focused on the Wnt/β-catenin signaling and cancer stemness markers.
[RESULTS] SOX7 was widely expressed in normal tissues, including stomach, but was frequently downregulated in GsCa due to promoter CpG methylation, which correlated with worse overall patient survival. Functionally, SOX7 restoration inhibited GsCa cell growth by inducing G0/G1 arrest, ferroptosis, and apoptosis. It also suppressed migration and invasion by inhibiting epithelial-mesenchymal transition (EMT) and cancer stemness. Mechanistically, SOX7 is localized to nuclear speckles and antagonized Wnt/β-catenin signaling through sequestering active β-catenin in the cytoplasm, directly binding to Wnt target gene promoters (e.g., c-MYC), and competitively β-catenin displacement. Bidirectional rescue experiments confirmed its tumor-suppressive functions dependent on inactivation of β-catenin.
[CONCLUSIONS] SOX7 is a tumor suppressor in GsCa frequently inactivated by promoter methylation. It suppresses tumorigenesis by direct antagonizing Wnt signaling, thereby inhibiting EMT and stemness. SOX7 promoter methylation is a potential biomarker for GsCa prognosis and detection.
[METHODS] SOX7 mRNA expression and promoter methylation were analyzed in GsCa. Functional impacts were assessed through assays for colony formation, proliferation (CCK-8), cell cycle/apoptosis (flow cytometry), migration/invasion (wound healing, Transwell), and ferroptosis. Mechanistic studies involving Western blot, immunofluorescence, dual-luciferase reporter assays, chromatin immunoprecipitation (ChIP)-qPCR, and bidirectional rescue experiments focused on the Wnt/β-catenin signaling and cancer stemness markers.
[RESULTS] SOX7 was widely expressed in normal tissues, including stomach, but was frequently downregulated in GsCa due to promoter CpG methylation, which correlated with worse overall patient survival. Functionally, SOX7 restoration inhibited GsCa cell growth by inducing G0/G1 arrest, ferroptosis, and apoptosis. It also suppressed migration and invasion by inhibiting epithelial-mesenchymal transition (EMT) and cancer stemness. Mechanistically, SOX7 is localized to nuclear speckles and antagonized Wnt/β-catenin signaling through sequestering active β-catenin in the cytoplasm, directly binding to Wnt target gene promoters (e.g., c-MYC), and competitively β-catenin displacement. Bidirectional rescue experiments confirmed its tumor-suppressive functions dependent on inactivation of β-catenin.
[CONCLUSIONS] SOX7 is a tumor suppressor in GsCa frequently inactivated by promoter methylation. It suppresses tumorigenesis by direct antagonizing Wnt signaling, thereby inhibiting EMT and stemness. SOX7 promoter methylation is a potential biomarker for GsCa prognosis and detection.
같은 제1저자의 인용 많은 논문 (5)
- A mGluR1-targeted radiotheranostic strategy visualizes lesions and potentiates antitumor efficacy in melanoma and pancreatic cancer.
- A Case of Angioimmunoblastic T-Cell Lymphoma Misdiagnosed as Eczema-Like Dermatitis in an Elderly Patient.
- Design, Synthesis and Biological Evaluation of Oxadiazole-Biphenyl Derivatives as Small Molecule Inhibitors Targeting PD-1/PD-L1 Immune Checkpoint.
- Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRAS G12D Inhibitor.
- Correction to "Phototheranostic Metal-Phenolic Networks with Antiexosomal PD-L1 Enhanced Ferroptosis for Synergistic Immunotherapy".